EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy of Intravesical Instillation Therapy with Low-Dose Tokyo-172 Bacillus Calmette-Guérin to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer and Treat Carcinoma in situ: A Multi-Institutional Retrospective Study

Takashi Tachibana, Masaomi Ikeda, Soichiro Shimura, Noriyuki Amano, Yasukiyo Murakami, Yasufumi Yamada, Dai Koguchi, Ryota Maeyama, Mizuho Kawamura, Yusuke Sakata, Masahiro Hagiwara, Kazumasa Matsumoto und 1 weitere

Urologia Internationalis · 2023

DOI: 10.1159/000527718 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Urologia Internationalis, 2023. Verfasst von Takashi Tachibana und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

There are various doses, durations, and strains of bacillus Calmette-Guérin (BCG) intravesical instillation therapy, but optimal treatment has not yet been established. We retrospectively investigated the efficacy and safety of low-dose BCG therapy for non-muscle-invasive bladder cancer (NMIBC) and carcinoma in situ (CIS) in a multicenter study.

Methods

From 1991 to 2019, 323 patients who received BCG therapy to prevent recurrence of NMIBC were analyzed as group A. Similarly, 147 patients who received BCG therapy for the treatment of CIS were analyzed as group B. Patients received low- or full-dose Tokyo-172 strain or full-dose Connaught strain, and the three strains were compared. Survival curves were estimated by the Kaplan-Meier method, and independent risk factors for intravesical recurrence were examined by multivariate logistic regression.

Results

Recurrence-free survival (RFS) in group A was significantly better for the Connaught strain than the low-dose Tokyo-172 strain (p = 0.026), but not between the low- and full-dose Tokyo-172 strains (p = 0.443). RFS of group B, cancer-specific survival, and progression-free survival in both groups did not show statistically significant differences. Logistic analysis of group A showed that for intravesical recurrence, only pT1 was a significant risk factor, and there were no differences between the BCG strain and dose and no significant factors in group B. There were also no differences in the completion rate in both groups, but adverse events such as urinary frequency and feeling of residual urine were significantly lower with the low-dose Tokyo-172 strain.

Conclusion

There was no difference in efficacy between the low- and full-dose Tokyo-172 strains, but to minimize adverse events, the low-dose Tokyo-172 strain may be worth considering.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsCarcinoma in SituHumansRetrospective StudiesBCG VaccineAdministration, IntravesicalTokyoNeoplasm Recurrence, LocalNeoplasm Invasiveness

Stichwörter der Autor:innen

Carcinoma in situInduction therapyLow-dose bacillus Calmette-GuérinNon-muscle-invasive bladder cancerTokyo-172 strain

Substanzen

BCG Vaccine

Autor:innen und Institutionen

  • Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan.
  • Department of Urology, Kitasato University Medical Center, Saitama, Japan.
  • Department of Urology, Sagamihara Kyodo Hospital, Kanagawa, Japan.
  • Department of Urology, Yokosuka City Uwamachi Hospital, Kanagawa, Japan.
  • Department of Urology, Higashiyamato Hospital, Tokyo, Japan.
  • Department of Urology, Sagamihara Hospital, Kanagawa, Japan.

Zitieren

APA

Tachibana, T., Ikeda, M., Shimura, S., Amano, N., Murakami, Y., Yamada, Y., Koguchi, D., Maeyama, R., Kawamura, M., Sakata, Y., Hagiwara, M., Matsumoto, K., & Iwamura, M. (2023). Efficacy of Intravesical Instillation Therapy with Low-Dose Tokyo-172 Bacillus Calmette-Guérin to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer and Treat Carcinoma in situ: A Multi-Institutional Retrospective Study. Urologia Internationalis. https://doi.org/10.1159/000527718

Vancouver

Tachibana T, Ikeda M, Shimura S, Amano N, Murakami Y, Yamada Y, et al. Efficacy of Intravesical Instillation Therapy with Low-Dose Tokyo-172 Bacillus Calmette-Guérin to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer and Treat Carcinoma in situ: A Multi-Institutional Retrospective Study. Urologia Internationalis. 2023. doi:10.1159/000527718

BibTeX
@article{Tachibana2023,
  author = {Tachibana, Takashi and Ikeda, Masaomi and Shimura, Soichiro and Amano, Noriyuki and Murakami, Yasukiyo and Yamada, Yasufumi and Koguchi, Dai and Maeyama, Ryota and Kawamura, Mizuho and Sakata, Yusuke and Hagiwara, Masahiro and Matsumoto, Kazumasa and Iwamura, Masatsugu},
  title = {Efficacy of Intravesical Instillation Therapy with Low-Dose Tokyo-172 Bacillus Calmette-Guérin to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer and Treat Carcinoma in situ: A Multi-Institutional Retrospective Study},
  journal = {Urologia Internationalis},
  year = {2023},
  doi = {10.1159/000527718}
}
Kostenlos starten →